PMID- 31096505
OWN - NLM
STAT- MEDLINE
DCOM- 20240129
LR  - 20240129
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 20
DP  - 2019 May
TI  - Efficacy and safety of moxibustion in patients with chronic prostatitis/chronic 
      pelvic pain syndrome: A systematic review protocol.
PG  - e15678
LID - 10.1097/MD.0000000000015678 [doi]
LID - e15678
AB  - BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a 
      common urogenital disease. Moxibustion is a complementary treatment option for 
      CP/CPPS. This systematic review will assess the efficacy and safety of 
      moxibustion as a sole or add-on therapy for CP/CPPS. METHODS: We will retrieve 
      randomized controlled trials (RCTs) of moxibustion for CP/CPPS from the following 
      databases: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, VIP, 
      Chinese Biomedical Database, China National Knowledge Infrastructure Database, 
      Wanfang Data, Chinese Medicine Database System, Google Scholar, 
      Clinicaltrials.gov, and China Clinical Trial Registry from their inception to 
      March 9, 2019, without language restrictions. RCTs comparing moxibustion with 
      active drugs or moxibustion + drugs with these same drugs alone will be included. 
      Primary outcomes will be the change in the total score of the National Institutes 
      of Health's Chronic Prostatic Inflammatory States Index (NIH-CPSI) after 
      moxibustion treatment. Secondary outcomes will include the scores of the 
      individual NIH-CPSI domains, response to treatment of CP/CPPS, leucocyte and 
      phosphatidylcholine corpuscle count in prostatic fluid, incidence of adverse 
      events (AEs), and incidence of moxibustion-related AEs. The Cochrane risk of bias 
      tool will be used for evaluating the risk of bias of individual trials. 
      Heterogeneity will be detected by the Cochran Q test and I-square test. A 
      random-effects model will be used to pool data in the meta-analysis. Risk ratio 
      and weighted or standardized mean difference will be used as the effect measures. 
      Three sets of subgroup analyses will be performed to explore the sources of 
      heterogeneity. Where appropriate, we will assess the likelihood of publication 
      bias based on funnel plots and quantitative tests. RESULTS: This study will 
      produce the systematic review evidence regarding moxibustion for treating CP/CPPS 
      based on current RCTs. CONCLUSION: This study will provide a clear basis for 
      understanding the efficacy and adverse reactions of moxibustion treatment for 
      CP/CPPS. PROSPERO REGISTRATION NUMBER: CRD42019121338.
FAU - Cao, Qianan
AU  - Cao Q
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Zhou, Xu
AU  - Zhou X
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Chen, Jianrong
AU  - Chen J
AD  - Department of Endocrinology, Second Affiliated Hospital, Chongqing Medical 
      University, Chongqing.
FAU - Zhong, Yuting
AU  - Zhong Y
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Zhang, Haifeng
AU  - Zhang H
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Ao, Qi
AU  - Ao Q
AD  - Department of internal medicine, Jiangxi Cancer Hospital, Nanchang, Jiangxi, 
      China.
FAU - Liu, Meilu
AU  - Liu M
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Nie, Heyun
AU  - Nie H
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Zhu, Weifeng
AU  - Zhu W
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
FAU - Fu, Yong
AU  - Fu Y
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Phosphatidylcholines)
SB  - IM
MH  - Humans
MH  - Male
MH  - Chronic Pain
MH  - Leukocyte Count
MH  - Medicine, Chinese Traditional
MH  - *Moxibustion/adverse effects/methods
MH  - *Pelvic Pain/therapy
MH  - Phosphatidylcholines/analysis
MH  - *Prostatitis/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC6531205
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/05/18 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/05/17
CRDT- 2019/05/18 06:00
PHST- 2019/05/18 06:00 [entrez]
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/05/17 00:00 [pmc-release]
AID - 00005792-201905170-00076 [pii]
AID - MD-D-19-03231 [pii]
AID - 10.1097/MD.0000000000015678 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 May;98(20):e15678. doi: 10.1097/MD.0000000000015678.